Guest Editor(s)

• Dr. Wei Zhang

  Department of Preventive Medicine and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA.

  Website | E-mail

• Dr. Brian Chiu

  Department of Public Health Sciences, The University of Chicago, Chicago, USA.

  Website | E-mail

Special Issue Introduction

For years, clinicians and researchers have been trying to discover better ways to diagnose human diseases, especially cancer, which is a leading cause of death globally. For many cancers, early detection and precise diagnosis could significantly improve cancer-related mortality and healthcare cost burden. At present, tissue biopsy pathology and imaging analyses are often the gold standard for cancer diagnosis and detection. Although extremely useful, tissue-based approaches are limited by various factors such as their invasive nature, possible exposure to radiation, tissue inaccessibility, as well as intra-tumoral heterogeneity. Analysis of circulating cell-free DNA (cfDNA), i.e., DNA fragments released by tumor cells or due to processes like apoptosis and necrosis, offers a promising alternative for cancer biomarker discovery, considering that cfDNA contains tumor-derived genetic and epigenetic information. In this special issue, we are interested in publishing research articles, short communications, technical notes, and review papers in the general area of applying cfDNA in the diagnosis of diseases. Papers on human cancers and other chronic diseases are all welcome.

Submission Deadline

31 Mar 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://jtggjournal.com/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/JTGG/?IssueId=345
Submission Deadline: 31 Mar 2020
Contacts: Jingxiu Li, Assistant Editor, assistant_editor@jtggjournal.com

Planned Papers

Type: Case Report

Title: liquid biopsy and Müllerian uterine sarcoma: a new tool for cancer detection? A case report

Authors: Francesca Malentacchi¹, Ivo Noci¹, Giulia Fantappiè¹, Dora Pavone¹, Irene Turrini¹, Serena Pillozzi²

Affiliations: ¹Department of Clinical, Experimental and Biomedical Sciences, University of Florence, Italy
²Medical Oncology Unit, AOU Careggi, Firenze, Italy

Abstract: Liquid biopsy is an emerging tool for the screening, diagnosis and monitoring treatment of cancer.
Uterine sarcomas comprise a small percentage of uterine malignancies (less than 10%) that have a higher incidence rate in women aged >50. Müllerian adenosarcoma is a subtype of uterine sarcoma a mesenchymal subtype, is a biphasic tumor composed of both sarcomatous stroma and benign epithelium. Hysterectomy and bilateral sapingo-oopherectomy, avoiding morcellation, are the standards of care.
Up to now no molecular target exists for treatment and for detection or monitoring. This case report evidences that liquid biopsy and circulating tumor DNA analysis may represent a new tool for characterization of Müllerian sarcoma and may open new prospective for management of patients affected by this cancer type.

---